MONSEY, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of WK Kellogg Co. (NYSE: KLG) (“Kellogg”) to Ferrero Group for $23.00 per share in cash.

Aspen has demonstrated strong underwriting profitability and value creation despite industry headwinds, supported by a hardening insurance market and disciplined capital allocation. The company's integrated 'One Aspen' approach and ACM platform differentiate it, enabling bespoke risk solutions and stable, growing fee income from third-party capital. Aspen continues to generate economic profit with solid free cash flow and an attractive valuation, with the market pricing in conservative growth assumptions.

I reiterate a Sell rating on Otis Worldwide Corporation, with a fair value of $82 per share, due to a persistently weak growth outlook. Otis faces ongoing headwinds from sluggish China real estate and global housing markets, resulting in declining new equipment sales. Management's optimism on China's recovery appears premature, especially amid continued property price declines and U.S.-China tariff uncertainties.

Aurora Innovation CEO Chris Urmson discusses the company's autonomous trucking service, the regulatory environment and partnership with Nvidia. He speaks with Ed Ludlow at the Sun Valley conference.

Apple, Visa and Mastercard reportedly won a legal victory in an antitrust lawsuit. The tech giant and the two payment firms convinced a federal judge to dismiss the lawsuit accusing them of colluding to stifle competition, Reuters reported Thursday (July 10).

Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market opportunity with minimal competition, as MC4R agonists address the root cause, unlike GLP-1s. Pipeline expansion, including oral and weekly MC4R agonists, positions Rhythm for long-term market dominance in rare obesity beyond 2040.

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DallasNews Corporation (NASDAQ: DALN) to Hearst for $14.00 in cash per share is fair to DallasNews shareholders. Halper Sadeh encourages DallasNews shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether DallasNews and.

Baker Hughes CEO Lorenzo Simonelli on Thursday said that despite short-term oil volatility, he still sees "long-term positive trends" for the industry.

DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 5,242,464 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.763 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, …

U.S. stocks are overbought — but overbought does not mean sell.

EQT Corp (NYSE:EQT) is down 1.5% at $54.06 at last glance, extending a pullback from its June 23, record high of $61.02.

Methode Electronics, Inc. (NYSE:MEI ) Q4 2025 Earnings Conference Call July 10, 2025 11:00 AM ET Company Participants Jonathan B. DeGaynor - President, CEO & Director Laura M.

The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI , July 10, 2025 /PRNewswire/ -- Royal Caribbean kicked off the countdown to a new era of family vacations, officially welcoming Star of the Seas * into the family. After nearly two years of construction at the Meyer Turku shipyard in Turku, Finland , the keys to the next revolutionary Icon Class ship were officially handed over to Royal Caribbean just a few weeks ahead of its August debut in Port Canaveral (Orlando), Florida.

Wells Fargo reportedly sees signs of an economic slowdown, with job creation slowing and inflation expected to rise.

Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going after patients ages 2 to < 7 years.

WARREN, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the completion and official opening of its fully functional, newly expanded corporate headquarters in Warren, New Jersey. The build-out and first-year operating costs were personally gifted by Founder and Chief Executive Officer Ryan Saadi, M.D., M.P.H., resulting in no expense to the Company or its shareholders.

CNBC's Steve Kovach joins the "Power Lunch" team to discuss Apple CEO Tim Cook's future with the company, Apple's AI struggles and more.

- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear. MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.

Company's New Jersey Division wins over a dozen awards, including Townhome Community of the Year for Middletown Walk Company's New Jersey Division wins over a dozen awards, including Townhome Community of the Year for Middletown Walk